Introducing ViroCell Biologics. The UK’s first clinical trial focused viral vector manufacturer.

ViroCell Biologics, founded in the UK by a prolific academic viral vector manufacturing team, has officially launched. Viral vectors are the primary delivery method for innovative vaccines such as the Oxford/Astra Zeneca COVID vaccine, as well as enabling inputs for the manufacture of the rapidly growing Cell and Gene Therapy sector (CGT).

ViroCell aims to be the supplier of choice for viral vectors and gene modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials. ViroCell has assembled an experienced viral vector manufacturing team to support its heavy operational demand and is now building out further manufacturing capability to address the current, acute supply chain bottlenecks worldwide. ViroCell is deploying significant capital and management talent around the viral vector design and manufacturing track record of Farzin Farzaneh, PhD – professor of molecular medicine at King’s College London, and expects to employ more than 50 professionals in the UK by the end of 2021.